Literature DB >> 23008061

Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer.

Allen M Chen1, Judy Li, Laurel A Beckett, Talia Zhara, Gregory Farwell, Derick H Lau, Regina Gandour-Edwards, Andrew T Vaughan, James A Purdy.   

Abstract

OBJECTIVES/HYPOTHESIS: To evaluate the responsiveness of human papillomavirus (HPV) -positive and HPV-negative oropharyngeal cancer to intensity-modulated radiotherapy (IMRT), using axial imaging obtained daily during the course of image-guided radiotherapy (IGRT). STUDY
DESIGN: Observational cohort study with matched-pair analysis of patients irradiated for HPV-positive and HPV-negative oropharygeal cancer. METHODS AND MATERIALS: Ten patients treated by IMRT to 70 Gy for locally advanced, HPV-positive squamous cell carcinoma of the oropharynx were matched to one HPV-negative control subject by age, gender, performance status, T-category, tumor location, and the use of concurrent chemotherapy. The gross tumor volume (GTV) was delineated on daily IGRT scans obtained via kilovoltage cone-beam computed tomography (CBCT). Mathematical modeling using fitted mixed-effects repeated measure analysis was performed to quantitatively and descriptively assess the trajectory of tumor regression.
RESULTS: Patients with HPV-positive tumors experienced a more rapid rate of tumor regression between day 1 of IMRT and the beginning of week 2 (-33% Δ GTV) compared to their counterparts with HPV-negative tumors (-10% Δ GTV), which was statistically significant (p<0.001). During this initial period, the average absolute change in GTV was -22.9 cc/week for HPV-positive tumors and -5.9 cc/week for HPV-negative tumors (p<0.001). After week 2 of IMRT, the rates of GTV regression were comparable between the two groups.
CONCLUSIONS: HPV-positive oropharyngeal cancers exhibited an enhanced response to radiation, characterized by a dramatically more rapid initial regression than those with HPV-negative tumors. Implications for treatment de-intensification in the context of future clinical trials and the possible mechanisms underlying this increased radiosensitivity will be discussed.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23008061     DOI: 10.1002/lary.23570

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  17 in total

1.  Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma--an in vivo and in vitro study.

Authors:  Lauri Jouhi; Neeta Datta; Suvi Renkonen; Timo Atula; Antti Mäkitie; Caj Haglund; Abdirisak Ahmed; Stina Syrjänen; Reidar Grénman; Eeva Auvinen; Sanna Lehtonen; Jaana Hagström
Journal:  Tumour Biol       Date:  2015-05-05

2.  Enhanced radiation sensitivity in HPV-positive head and neck cancer.

Authors:  Randall J Kimple; Molly A Smith; Grace C Blitzer; Alexandra D Torres; Joshua A Martin; Robert Z Yang; Chimera R Peet; Laurel D Lorenz; Kwangok P Nickel; Aloysius J Klingelhutz; Paul F Lambert; Paul M Harari
Journal:  Cancer Res       Date:  2013-06-07       Impact factor: 12.701

3.  Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.

Authors:  John V Hegde; Narek Shaverdian; Megan E Daly; Carol Felix; Deborah L Wong; Michael H Rosove; Jordan H Garst; Pin-Chieh Wang; Darlene Veruttipong; Shyam Rao; Ruben C Fragoso; Jonathan W Riess; Michael L Steinberg; Allen M Chen
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

4.  Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions.

Authors:  Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-08       Impact factor: 3.497

5.  Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI-tri-60Co teletherapy device.

Authors:  Govind Raghavan; Amar U Kishan; Minsong Cao; Allen M Chen
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

6.  Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history.

Authors:  Kara S Davis; John A Vargo; Robert L Ferris; Steven A Burton; James P Ohr; David A Clump; Dwight E Heron
Journal:  Oral Oncol       Date:  2014-08-28       Impact factor: 5.337

7.  No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.

Authors:  R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-10       Impact factor: 2.503

8.  Gold nanoparticles enhance X-ray irradiation-induced apoptosis in head and neck squamous cell carcinoma in vitro.

Authors:  Shun Teraoka; Yasumasa Kakei; Masaya Akashi; Eiji Iwata; Takumi Hasegawa; Daisuke Miyawaki; Ryohei Sasaki; Takahide Komori
Journal:  Biomed Rep       Date:  2018-08-22

9.  Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]).

Authors:  Terence T Sio; Pamela J Atherton; Brandon J Birckhead; David J Schwartz; Jeff A Sloan; Drew K Seisler; James A Martenson; Charles L Loprinzi; Patricia C Griffin; Roscoe F Morton; Jon C Anders; Thomas J Stoffel; Robert E Haselow; Rex B Mowat; Michelle A Neben Wittich; James D Bearden; Robert C Miller
Journal:  Support Care Cancer       Date:  2016-04-14       Impact factor: 3.603

10.  EGFR Protein Expression Relates with Tumor Histology, Methylation Status of EGFR and HPV16 E6 Viral Load in Oropharyngeal Carcinoma.

Authors:  Yo Suzuki; Yuki Fukumura; Miki Asahina; Mitsuhisa Fujimaki; Shinichi Ohba; Fumihiko Matsumoto; Isao Kurahayashi; Takashi Yao; Katsuhisa Ikeda
Journal:  Head Neck Pathol       Date:  2021-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.